These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35682540)

  • 21. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.
    Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H
    Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
    Ivanov VN; Zhou H; Partridge MA; Hei TK
    Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
    Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
    PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
    Shlyakhtina Y; Pavet V; Gronemeyer H
    Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.
    Reis CR; van der Sloot AM; Szegezdi E; Natoni A; Tur V; Cool RH; Samali A; Serrano L; Quax WJ
    Biochemistry; 2009 Mar; 48(10):2180-91. PubMed ID: 19236007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
    Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
    Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
    Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5.
    Fei HR; Yuan C; Wang GL; Zhao Y; Li ZJ; Du X; Wang FZ
    Phytomedicine; 2019 Sep; 62():152950. PubMed ID: 31102888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. H-Ras regulation of TRAIL death receptor mediated apoptosis.
    Chen JJ; Bozza WP; Di X; Zhang Y; Hallett W; Zhang B
    Oncotarget; 2014 Jul; 5(13):5125-37. PubMed ID: 25026275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib.
    Edagawa M; Kawauchi J; Hirata M; Goshima H; Inoue M; Okamoto T; Murakami A; Maehara Y; Kitajima S
    J Biol Chem; 2014 Aug; 289(31):21544-61. PubMed ID: 24939851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway.
    Yi L; Zongyuan Y; Cheng G; Lingyun Z; Guilian Y; Wei G
    Cancer Sci; 2014 May; 105(5):520-7. PubMed ID: 24612139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
    Meijer A; Kruyt FA; van der Zee AG; Hollema H; Le P; ten Hoor KA; Groothuis GM; Quax WJ; de Vries EG; de Jong S
    Br J Cancer; 2013 Nov; 109(10):2685-95. PubMed ID: 24136147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
    Chen S; Fu L; Raja SM; Yue P; Khuri FR; Sun SY
    Mol Cancer; 2010 Jan; 9():23. PubMed ID: 20113484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
    Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
    Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
    Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
    Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative binding to DR4 and DR5 receptors of TRAIL and BNNTs/PAHE/mPEG-DSPE/TRAIL nanoparticles.
    Guillaume YC; André C
    J Mol Recognit; 2017 Jul; 30(7):. PubMed ID: 28120533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.